366 related articles for article (PubMed ID: 33402095)
41. Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings.
Geroult S; Phillips RO; Demangel C
J Wound Care; 2014 Aug; 23(8):417-8, 422-4. PubMed ID: 25139600
[TBL] [Abstract][Full Text] [Related]
42. Buruli ulcer (Mycobacterium ulcerans infection).
Walsh DS; Portaels F; Meyers WM
Trans R Soc Trop Med Hyg; 2008 Oct; 102(10):969-78. PubMed ID: 18657836
[TBL] [Abstract][Full Text] [Related]
43. Nutritional status and wound healing in patients with Mycobacterium ulcerans disease (Buruli ulcer): a pilot study from rural Côte d’Ivoire.
Ugai K; Koffi DY; Kouadio K; Yao A; Yotsu RR
Eur J Dermatol; 2022 Apr; 32(2):227-236. PubMed ID: 35866902
[TBL] [Abstract][Full Text] [Related]
44. Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas.
Ortiz RH; Leon DA; Estevez HO; Martin A; Herrera JL; Romo LF; Portaels F; Pando RH
Clin Exp Immunol; 2009 Aug; 157(2):271-81. PubMed ID: 19604267
[TBL] [Abstract][Full Text] [Related]
45. [Micronecta sp (Corixidae) and Diplonychus sp (Belostomatidae), two aquatic Hemiptera hosts and/or potential vectors of Mycobacterium ulcerans (pathogenic agent of Buruli ulcer) in Cote d'Ivoire].
Doannio JM; Konan KL; Dosso FN; Koné AB; Konan YL; Sankaré Y; Ekaza E; Coulibaly ND; Odéhouri KP; Dosso M; Sess ED; Marsollier L; Aubry J
Med Trop (Mars); 2011 Feb; 71(1):53-7. PubMed ID: 21585092
[TBL] [Abstract][Full Text] [Related]
46. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.
Martins TG; Trigo G; Fraga AG; Gama JB; Longatto-Filho A; Saraiva M; Silva MT; Castro AG; Pedrosa J
PLoS Negl Trop Dis; 2012; 6(11):e1925. PubMed ID: 23209864
[TBL] [Abstract][Full Text] [Related]
47. Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection.
Wanda F; Nkemenang P; Ehounou G; Tchaton M; Comte E; Toutous Trellu L; Masouyé I; Christinet V; O'Brien DP
BMC Infect Dis; 2014 Jul; 14():423. PubMed ID: 25073531
[TBL] [Abstract][Full Text] [Related]
48. [Contribution of gene amplification in Mycobacterium ulcerans detection in exudates and cutaneous biopsies in Côte d'Ivoire].
Ekaza E; Kacou-N'Douba A; Oniangué NC; Ehuie P; N'guessan KR; Aka N; Bouzid SA; Faye-Ketté H; Dosso M
Bull Soc Pathol Exot; 2004 May; 97(2):95-6. PubMed ID: 15255348
[TBL] [Abstract][Full Text] [Related]
49. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.
Schütte D; Umboock A; Pluschke G
Br J Dermatol; 2009 Feb; 160(2):273-83. PubMed ID: 19016694
[TBL] [Abstract][Full Text] [Related]
50. Landscape diversity related to Buruli ulcer disease in Côte d'Ivoire.
Brou T; Broutin H; Elguero E; Asse H; Guegan JF
PLoS Negl Trop Dis; 2008 Jul; 2(7):e271. PubMed ID: 18665259
[TBL] [Abstract][Full Text] [Related]
51. Statistical modeling based on structured surveys of Australian native possum excreta harboring
Vandelannoote K; Buultjens AH; Porter JL; Velink A; Wallace JR; Blasdell KR; Dunn M; Boyd V; Fyfe JAM; Tay EL; Johnson PDR; Windecker SM; Golding N; Stinear TP
Elife; 2023 Apr; 12():. PubMed ID: 37057888
[TBL] [Abstract][Full Text] [Related]
52. Tracing Mycobacterium ulcerans along an alimentary chain in Côte d'Ivoire: A one health perspective.
Hammoudi N; Dizoe S; Saad J; Ehouman E; Davoust B; Drancourt M; Bouam A
PLoS Negl Trop Dis; 2020 May; 14(5):e0008228. PubMed ID: 32463813
[TBL] [Abstract][Full Text] [Related]
53. Membrane Active Immunomodulator As a Novel Therapy for an Infectious Bacterial Disease, Buruli Ulcer.
Izbicka E; Streeper RT; Louden C
In Vivo; 2022; 36(6):2615-2629. PubMed ID: 36309402
[TBL] [Abstract][Full Text] [Related]
54. Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa.
Wadagni AC; Steinhorst J; Barogui YT; Catraye PM; Gnimavo R; Abass KM; Amofa G; Frimpong M; Sarpong FN; van der Werf TS; Phillips R; Sopoh GE; Johnson CR; Stienstra Y
PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007866. PubMed ID: 31658295
[TBL] [Abstract][Full Text] [Related]
55. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.
Liu Y; Gao Y; Liu J; Tan Y; Liu Z; Chhotaray C; Jiang H; Lu Z; Chiwala G; Wang S; Makafe G; Islam MM; Hameed HMA; Cai X; Wang C; Li X; Tan S; Zhang T
Nat Commun; 2019 Jan; 10(1):524. PubMed ID: 30705268
[TBL] [Abstract][Full Text] [Related]
56. Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.
Sáez-López E; Millán-Placer AC; Lucía A; Ramón-García S
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011867. PubMed ID: 38573915
[TBL] [Abstract][Full Text] [Related]
57. Locally Confined Clonal Complexes of Mycobacterium ulcerans in Two Buruli Ulcer Endemic Regions of Cameroon.
Bolz M; Bratschi MW; Kerber S; Minyem JC; Um Boock A; Vogel M; Bayi PF; Junghanss T; Brites D; Harris SR; Parkhill J; Pluschke G; Lamelas Cabello A
PLoS Negl Trop Dis; 2015; 9(6):e0003802. PubMed ID: 26046531
[TBL] [Abstract][Full Text] [Related]
58. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
[TBL] [Abstract][Full Text] [Related]
59. Buruli ulcer in Nigeria: results of a pilot case study in three rural districts.
Ukwaja KN; Meka AO; Chukwuka A; Asiedu KB; Huber KL; Eddyani M; Chukwu JN; Anyim MC; Nwafor CC; Oshi DC; Madichie NO; Ekeke N; Njoku M; Ntana K
Infect Dis Poverty; 2016 Apr; 5():39. PubMed ID: 27105826
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
